InterCure Ltd
TASE:INCR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
444
1 254
|
Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
InterCure Ltd
Common Stock
InterCure Ltd
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
I
|
InterCure Ltd
TASE:INCR
|
Common Stock
â‚Ş643.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Common Stock
$58m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
||
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Common Stock
$774k
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
||
Mediwound Ltd
NASDAQ:MDWD
|
Common Stock
$186k
|
CAGR 3-Years
32%
|
CAGR 5-Years
18%
|
CAGR 10-Years
12%
|
||
S
|
Seach Medical Group Ltd
TASE:SEMG
|
Common Stock
â‚Ş70.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
488%
|
CAGR 10-Years
0%
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Common Stock
â‚Ş13.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
6%
|
InterCure Ltd
Glance View
InterCure Ltd. engages in the business of medical cannabis and biomedicine. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
See Also
What is InterCure Ltd's Common Stock?
Common Stock
643.2m
ILS
Based on the financial report for Dec 31, 2023, InterCure Ltd's Common Stock amounts to 643.2m ILS.
What is InterCure Ltd's Common Stock growth rate?
Common Stock CAGR 5Y
32%
Over the last year, the Common Stock growth was 2%. The average annual Common Stock growth rates for InterCure Ltd have been 12% over the past three years , 32% over the past five years .